Sen-Jam Pharmaceutical is developing a promising drug for the prevention of alcohol-induced hangovers as the condition is classified as a separate entity that must be treated medically

Sen-Jam Pharmaceutical is developing a promising hangover prevention drug that treats the newly understood pathology of inflammation.

HUNTINGTON, NY, March 16, 2022 /PRNewswire/ — Since the discovery of alcohol thousands of years ago, drinkers enjoy consuming alcoholic beverages, but also suffer from the negative effects of drinking the next day. This so-called alcoholic hangover is defined as the combination of negative mental and physical symptoms that can be experienced after a single episode of drinking, beginning when the blood alcohol level (BAC) approaches zero.

Indeed, the hangover felt the day after an evening of alcohol consumption can have a significant impact on the planned activities. For example, research has shown that hangovers negatively impact work performance (both presenteeism and absenteeism), lower student performance, and significantly impair driving performance. Social activities such as get-togethers with friends and family may be canceled and mood changes during the hangover state, interfering with social interactions. However, in today’s 24/7 society, many people live in the fast lane and want to enjoy all aspects of life to the fullest. After a busy day at work or as a student, a pleasant evening of drinking should not be followed by a hangover, as these drinkers also want to perform well the next day. Given this, it is understandable that the vast majority of drinkers would be supportive of the development of an effective and safe hangover treatment, and willing to purchase and use it once it becomes available. In fact, this interest was validated in a recent study in the Netherlands.

Pathology

Although some individual ingredients have shown promise, a search of the scientific literature reveals that there are currently no effective and safe hangover treatments on the market. Given its significant socio-economic consequences, it is surprising that so little research has been devoted to the development of treatments for hangovers. The lack of effective hangover treatments is caused by the lack of understanding of alcoholic hangovers. For decades, hangovers were thought to be caused by dehydration. More recent research has refuted this hypothesis. Current research on alcohol metabolism has revealed that drinking alcohol causes an inflammatory reaction that is likely responsible for the development of alcoholic hangover. It is believed that by neutralizing this inflammatory response, hangovers can be reduced or prevented. Since none of the hangover treatments on the market (which claim to have) have a mechanism of action that reduces this inflammatory response, it is understandable that these products are not effective in reducing or preventing hangovers.

Recently, the International Classification of Diseases 11th Revision (ICD-11) listed alcoholic hangover as a separate entity. This is in line with the US Food and Drug Administration (FDA) which considers hangovers a disease and requires treatments to be registered as drugs. Listing alcoholic hangover in ICD-11 has significant implications, as disease claims are prohibited for dietary supplements and foods that include all currently marketed hangover treatments. As a result, the FDA regularly issues warning letters to companies that do not comply with their regulations.

Finally a legitimate drug with clinical viability ushers in a bright new day

However, there is hope on the horizon. Sen-Jam Pharmaceutical is developing a new hangover treatment, SJP-001, comprising a combination of naproxen (a nonsteroidal anti-inflammatory drug (NSAID), pain reliever) and fexofenadine (a H1-antagonist, antihistamine drug). The innovative life science company actually has an open New Drug Application (IND) from the FDA to begin a Phase I and II clinical trial. Once SJP-001 is approved by the FDA, the new drug should be available both over the counter and by prescription. The mechanism of action of SJP-001 is to reduce the inflammatory response after alcohol consumption, which should then reduce or prevent a hangover the next day. As naproxen and fexofenadine have been used successfully for decades to treat pain and allergies respectively, there is a tremendous amount of evidence to suggest that SJP-001 is safe. Additionally, the results of a recent pilot study showed that SJP-001 was significantly more effective in reducing hangover severity than placebo. However, the sample size of this study was small and further research is warranted. Therefore, in the near future, an extensive clinical trial will be conducted to further evaluate the efficacy of SJP-001. In this study, in a large group of drinkers, the effects of SJP-001 on hangover severity will be investigated, including assessments of immune fitness biomarkers to demonstrate the mechanism of action of SJP-001. . Sen-Jam has obtained usage and formulation patents in the United States, Europe, Australia, Japan, Mexico& South Africa and have patents pending in 6 other counties, all of which could benefit from this revolutionary solution.

For anyone who likes to drink alcohol but suffers from occasional hangovers, it is hoped that these promising developments will prove successful. Until then, the best way to prevent a hangover is to moderate alcohol consumption or abstain completely.

Jackie IversenRPh, MS, Author, Founder and Head of Clinical Development at Sen-Jam Pharmaceutical

About Sen-Jam Pharmaceutical

At Sen-Jam Pharmaceutical, we disrupt pain and inflammation. Sen-Jam Pharmaceutical’s mission is to improve the well-being of society by developing treatments that are safe, effective and accessible to everyone. Sen-Jam reuses small molecules to develop new therapies for high unmet needs with a focus on improving clinical outcomes. Using proprietary patented technology and the 505(b)2 fast track, Sen-Jam is on a mission to revolutionize pain treatment and the pain relief business. Information for investors available on Wefunder. Learn more at www.sen-jam.com.

Contact information:

Pharmaceutical Sen-Jam
Christine Leonard
781-913-1902
[email protected]

SOURCE Sen-Jam Pharmaceutical

Comments are closed.